Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Canopy Growth Corp T.WEED

Alternate Symbol(s):  T.WEED.DB | CGC

Canopy Growth Corporation is a cannabis company. It delivers innovative products with a focus on premium and mainstream cannabis brands, including Doja, 7ACRES, Tweed, and Deep Space, in addition to category-defining vaporizer technology made in Germany by Storz & Bickel. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. International markets cannabis segment includes the production, distribution, and sale of a range of cannabis and hemp products internationally. Storz & Bickel segment includes the production, distribution, and sale of vaporizers. This Works segment includes the production, distribution and sale of beauty, skincare, wellness and sleep products.


TSX:WEED - Post by User

Bullboard Posts
Comment by George98on Dec 29, 2019 11:51am
140 Views
Post# 30498718

RE:RE:P/S around 25

RE:RE:P/S around 25

Well, let's see what happened in the last quarter:

Recreational cannabis revenue, the biggest portion of CGC’s revenue, fell 11% from $68.9 million CAD to $61 million CAD. Even though medical and international sales rose during the quarter, total gross revenue fell 2.9%.

Total sales in volume terms (kilograms and equivalents) rose 13%. Total sales volume was 10,549 kilograms and equivalents in the latest quarter against 9,326 kilograms in the prior quarter. Comparing the June quarter with the December quarter, volume increased only 4.4%.
So that means the effective cannabis price fell this quarter. They sold 13% more product and the gross revenue fall by 2.9%.

After the acquisitions, the adjusted FCF widened to loss of $824 million CAD from a loss of $414 million CAD. This is an increase in adjusted-FCF losses of 99%.

If CGC keeps losing $824 million CAD each quarter, the billions you depend on  will be mostly spent BEFORE the next year end.

Therefore,  your ignorance is at least remarkable.

Bullboard Posts